Author:
Silva Rai C.,Santos Cleydson B. R.,Taft Carlton A.,Silva Guilherme M.,de Paula da Silva Carlos Henrique Tomich
Publisher
Springer International Publishing
Reference91 articles.
1. Pan American Health Organization: Leishmaniasis: Epidemiological Report in the Americas: Washington: Pan American Health Organization (2022). www.paho.org/leishmaniasis
2. Sundar, S., Singh, B.: Emerging therapeutic targets for treatment of leishmaniasis. Exp. Opin. Therap. Targ. 22, 467–486 (2018)
3. Croft, S.L., Sundar, S., Fairlamb, A.H.: Drug resistance in leishmaniasis. Clinic. Microb. Rev. 19, 111–126 (2006)
4. Faraut-gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B., Marty, P., Michel, G., Faugère, Dumon, H.: In vitro and in vivoresistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimic. Agent. Chemoth. 41, 827–830 (1997)
5. Lira, R., Sundar, S., Makharia, A., Kenney, R., Gam, A., Saraiva, E., Sacks, D.: Evidence that the high incidence of treatment failures in Indian kalaazar is due to the emergence of antimonyresistant strains of Leishmania donovani. J. Infec. Diseas. 180, 564–567 (1999)